# 2026-19231: Diphenidine Banned: Obscure Drug Joins Schedule I No-Medical-Use Club

2026-19231, Schedules of Controlled Substances: Placement of Diphenidine in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-09-21, effective 2026-10-21; PRIA reads it as touching household money (as of 2026-09-28).

- Canonical: https://policyrisk.com/federal-register/2026-19231
- As of: 2026-09-28
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19231
- Title: Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 59695
- Published: 2026-09-21
- Effective: 2026-10-21
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-28

## In one line

Diphenidine Banned: Obscure Drug Joins Schedule I No-Medical-Use Club

## Summary

Starting October 21, 2026, diphenidine and its related forms will be officially listed as Schedule I drugs, meaning they’re considered highly controlled with no accepted medical use. This change affects anyone who makes, sells, studies, or even possesses diphenidine, bringing strict rules and serious penalties. The move helps the U.S. follow international drug laws and keep communities safer.

## Abstract

With the issuance of this final rule, the Drug Enforcement Administration places the substance diphenidine (1-(1,2- diphenylethyl)piperidine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle diphenidine.

## Effects PRIA read

- Diphenidine placed in Schedule I: cost, high. On October 21, 2026, diphenidine (including its salts, isomers, and related forms) is officially listed in Schedule I. This means possession, manufacture, sale, import, export, or other handling of diphenidine is unlawful unless you are authorized, and unauthorized activity may lead to administrati…
- You must register to handle diphenidine: cost, medium. Any person who wants to handle diphenidine (manufacture, distribute, import, export, research, or possess) must register with the DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. If you currently handle diphenidine and are not registered, you must apply for registration an…
- Research continuation window and expedited hearings: benefit, medium. If, on October 21, 2026, you are conducting research on diphenidine and are already registered to research another Schedule I substance, you may continue that diphenidine research if you submit a completed registration or modification application within 90 calendar days after the rule takes effect.…
- Schedule I compliance duties for registrants: cost, medium. Registered handlers of diphenidine must meet Schedule I controls: security and employee screening, labeling and packaging rules, manufacturing quotas, inventory (initial inventory on first handling and then every two years), records and reporting (including reports to Automation of Reports and Cons…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-20749](https://policyrisk.com/federal-register/2026-20749): Vladimir Romaniv, P.A.; Decision and Order, 2026-10-09
- [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09

## Sources
- [2026-19231 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/21/2026-19231/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)
- [2026-19231 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-21/pdf/2026-19231.pdf)

## Related
- [Previous: 2026-19223, Public Access to Information](https://policyrisk.com/federal-register/2026-19223)
- [Next: 2026-19270, Safety Zone; Illinois River, Morris, IL](https://policyrisk.com/federal-register/2026-19270)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19231 (as of 2026-09-28).